|Bid||262.63 x 900|
|Ask||262.84 x 800|
|Day's range||259.03 - 263.40|
|52-week range||228.00 - 459.75|
|Beta (3Y monthly)||1.03|
|PE ratio (TTM)||46.89|
|Earnings date||1 Aug 2019|
|Forward dividend & yield||N/A (N/A)|
|1y target est||334.38|
While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...
The Company will host a conference call to discuss the results on Thursday, August 1, 2019, at 8:00 a.m. EDT. Michael R. Minogue, Chairman, President and Chief Executive Officer and Todd Trapp, Chief Financial Officer, will host the conference call.
Today we'll evaluate Abiomed, Inc. (NASDAQ:ABMD) to determine whether it could have potential as an investment idea...
We often see insiders buying up shares in companies that perform well over the long term. On the other hand, we'd be...
Abiomed’s (ABMD) Impella platform is being featured today at a Washington, D.C., event showcasing innovations in medical technology that improve healthcare for women. Abiomed’s participation supports its Women’s Initiative for Heart Recovery, which provides education and raises awareness of women’s cardiovascular diseases and the opportunity for heart recovery. One young woman who benefited from heart recovery with Impella support is Iman Dorty, who is speaking at today’s event.
Abiomed (ABMD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Abiomed, Inc. , a leading provider of breakthrough heart support technologies, today announced that Michael R. Minogue, Chairman, President and Chief Executive Officer
Use of early identification protocol leads to higher survival and native heart recovery, as demonstrated in FDA studies
Improves upon AMI cardiogenic shock historical survival of 50%
Abiomed announces today that the Impella CP with SmartAssist, which is designed to improve patient outcomes with advanced algorithms and simplified patient management, will be commercially available beginning at the 2019 Society for Cardiovascular Angiography & Interventions Scientific Sessions through a controlled launch process at select sites.
Abiomed (ABMD) announces the U.S. FDA has approved the expansion of the Impella 5.0 and Impella LD PMA labeling for the treatment of cardiogenic shock. The Impella 5.0 and the Impella LD are forward flow heart pumps that deliver up to 5 L/min, stabilizing a patient’s hemodynamics, unloading the left ventricle, and perfusing the end organs, allowing for the potential of native heart recovery or return to heart function baseline. The Impella 5.0 is implanted through the femoral or axillary artery and the Impella LD is implanted directly into the aorta.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...
These two med-tech companies failed to impress investors in the first quarter. Is the bull case for owning these stocks still intact?
The medical device maker's first earnings report as a public company featured explosive revenue growth and upbeat full-year guidance.
Medical devices can be ultra reliable, lucrative business, but there are plenty of ways for companies to blow it, too.